Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Boston Therapeutics, Inc. (BTHE) And America's Sugar Monster 0 comments
    Oct 25, 2013 4:03 PM | about stocks: BTHE

    The formal description for Boston Therapeutics is of a pharmaceutical company focused on the development of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes. But the company's potential, as an investment and in terms of its possible effect on the tens of millions of people with Type 2 diabetes, is far more dramatic. CEO David Platt is blunt about it, saying in a recent interview with the New Hampshire Union Leader "We believe that what we have in our hands is an absolute blockbuster".

    The blockbuster in question is the company's one-of-a-kind proprietary polysaccharide, PAZ320, that represents a totally new way of treating type 2 diabetes, currently afflicting over 25 million people in the U.S. alone. PAZ320 is a chewable, locally acting complex carbohydrate-based compound that works in the gastrointestinal tract to directly block the enzymes that digest sugar. The demonstrated result is a dramatic reduction in the amount of glucose in the blood stream from carbohydrate rich meals. A phase II study of PAZ320 showed a 40 percent reduction of post-meal glucose in the blood of 45 percent of patients treated with PAZ320. There's never been anything like it.

    In spite of the enormous possibilities for Boston Therapeutics, CEO David Platt seems even more enthused about the development's potential benefit for public health. With obesity becoming the country's number one health issue, and even young people being faced with type 2 diabetes at levels never before experienced, Platt has an almost missionary zeal for taming the nation's sugar monster. In the same newspaper interview, he emphasized the deadly and critical nature of the challenge, saying "It's very simple. Sugar kills. End of story".

    For additional information, visit the company's website at BostonTI.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: BTHE
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.